# Cascadian Therapeutics, Inc.

Cascadian Therapeutics, Inc. is a company headquartered in Seattle, WA, United States.

## Company overview

- **Legal name:** Cascadian Therapeutics, Inc.
- **Former names in filing history:** Oncothyreon Inc. (2007-09-14 to 2016-06-09); Biomira CORP (2007-09-12 to 2007-09-27)
- **Classification:** Company
- **Industry (SIC):** 8731 — Services-Commercial Physical & Biological Research
- **Headquarters:** Seattle, WA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001412067

## About

Cascadian Therapeutics, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001412067, and its reported industry is Services-Commercial Physical & Biological Research. In 10-K filed on 2018-03-08, it reported net income of USD -56,934,000; total assets of USD 120,825,000 for the fiscal period ended 2017-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2017 (period ended 2017-12-31)

- **Net income:** -$56.9M (USD -56,934,000)
- **Total assets:** $120.8M (USD 120,825,000)
- **Cash and equivalents:** $16.8M (USD 16,777,000)
- **Operating cash flow:** -$50.0M (USD -49,981,000)

### FY2016 (period ended 2016-12-31)

- **Net income:** -$57.7M (USD -57,705,000)
- **Total assets:** $83.3M (USD 83,265,000)
- **Cash and equivalents:** $13.7M (USD 13,721,000)

### FY2015 (period ended 2015-12-31)

- **Net income:** -$32.6M (USD -32,581,000)
- **Total assets:** $96.6M (USD 96,574,000)
- **Cash and equivalents:** $27.9M (USD 27,850,000)
- **Operating cash flow:** -$28.9M (USD -28,870,000)
- **Later filings:** Operating cash flow: shown as originally filed; later filings report different values for the same periods.

### FY2014 (period ended 2014-12-31)

- **Net income:** -$50.0M (USD -49,963,000)
- **Total assets:** $103.4M (USD 103,411,000)
- **Cash and equivalents:** $10.5M (USD 10,454,000)
- **Operating cash flow:** -$48.4M (USD -48,367,000)
- **Later filings:** Net income, Total assets: shown as originally filed; later filings report different values for the same periods.

## Recent SEC filings

- Form 8-K — filed 2018-03-09 — period 2018-03-09 — FORM 8-K
- Form 10-K — filed 2018-03-08 — period 2017-12-31 — 10-K
- Form 8-K — filed 2018-02-07 — period 2018-02-01 — 8-K
- Form SC 13G — filed 2018-02-01
- Form 8-K — filed 2018-01-31 — period 2018-01-30 — 8-K
- Form 8-K — filed 2017-12-07 — period 2017-12-04 — 8-K
- Form 10-Q — filed 2017-11-08 — period 2017-09-30 — QUARTERLY REPORT
- Form 8-K — filed 2017-11-08 — period 2017-11-08 — CURRENT REPORT
- Form 10-Q — filed 2017-08-08 — period 2017-06-30 — QUARTERLY REPORT
- Form 8-K — filed 2017-08-08 — period 2017-08-08 — CURRENT REPORT
- Form 8-K — filed 2017-06-09 — period 2017-06-08 — FORM 8-K
- Form 10-Q — filed 2017-05-09 — period 2017-03-31 — 10-Q

---

Updated: 2026-10-23T20:08:00Z

Canonical page: https://altss.com/profile/cascadian-therapeutics-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology